Jump to main content
Jump to site search

Issue 13, 2013
Previous Article Next Article

Determination of L41, a novel cyclin-dependent kinase 1 inhibitor, in rat plasma by HPLC-UV and its application to a pharmacokinetic study

Author affiliations

Abstract

[(E)-3-(2-chlorophenyl)-1-(2-hydroxy-4,6-dimethoxy-3-(1,2,3,6-tetrahydropyridine-4-yl)phenyl)-2-propylene-1-one], L41, was found to be a potent cyclin-dependent kinase 1 inhibitor. To study its pharmacokinetic characteristics, a simple, specific, sensitive and reproducible HPLC method was developed and validated to quantitatively determine L41 in rat plasma. L41 and amlodipine besylate (internal standard, IS) were extracted from rat plasma by a simple liquid–liquid extraction process with ethyl acetate. Chromatographic separation was performed on an Agela C18 column and an isocratic mobile phase [methanol–water (containing 50 mM ammonium acetate), 77 : 23, v/v, pH 6.5] at a flow rate of 1 mL min−1 with a total run time of 10 min. The UV absorbance at 343 nm was recorded. L41 and IS eluted at 5.1 and 8.9 min, respectively. The calibration plot was linear over the concentration ranging of 15–1200 ng mL−1 (r > 0.998). The intra- and inter-day precisions of analysis were <12% and accuracy ranged from 93.5 to 106.3%. The validated HPLC method was successfully applied to the pharmacokinetic study of L41 in rats after a single intravenous and three oral administrations.

Graphical abstract: Determination of L41, a novel cyclin-dependent kinase 1 inhibitor, in rat plasma by HPLC-UV and its application to a pharmacokinetic study

Back to tab navigation

Article information


Submitted
01 Feb 2013
Accepted
16 Apr 2013
First published
17 Apr 2013

Anal. Methods, 2013,5, 3278-3284
Article type
Paper

Determination of L41, a novel cyclin-dependent kinase 1 inhibitor, in rat plasma by HPLC-UV and its application to a pharmacokinetic study

G. Wang, Y. Zong, X. Zhao, W. Xu and W. Wang, Anal. Methods, 2013, 5, 3278
DOI: 10.1039/C3AY40189H

Social activity

Search articles by author

Spotlight

Advertisements